Michael Pourdehnad, Senior Vice President, Head of Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb, shared on LinkedIn:
“For me, early clinical development is where the curve bends. It’s where bold science first demonstrates the potential to change outcomes for patients. One of the most satisfying aspects of my team’s work has been leveraging the collective experience and data of Bristol Myers Squibb’s cell therapy organization from the earliest stages to quickly generate the insights needed to recognize when an asset may truly be transformative.
It’s amazing to now see those insights hold up as results come in from registrational trials!”
Read the full article about Bristol Myers Squibb’s cell therapy trial here.
You may also be interested in: The Big Questions in Cancer Immunotherapy: Can Cell Therapy Succeed in Solid Tumors?
